Neurogene Inc (NGNE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $495.37M
Last updated: Nov 17, 2026 at 11:06 AM ET
Neurogene Inc (NGNE) Competitors
The companies most similar to Neurogene are Regenxbio (RGNX), Gyre Therapeutics (GYRE) and PepGen (PEPG). By market cap, Neurogene ranks 6th of the 13 companies on this page; Nuvectis Pharma (NVCT) is the largest at $696.03M.
Peer Comparison
NGNE's ROIC of -28.5% is below the peer median of -7.4%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Neurogene (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Regenxbio Inc (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| PepGen Ltd (PEPG) | $410.98M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Opus Genetics, Inc. (IRD) | $384.68M | N/A | 52.0x | 0.0% | -145.1% | -63.1% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| Geron Corporation (GERN) | $622.98M | N/A | 2.9x | -22.0% | -7.4% | 27.4% | 0.00% |
| Ginkgo Bioworks Holdings (DNA) | $622.97M | N/A | 6.1x | -192.0% | N/A | -5.7% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | $319.27M | N/A | N/A | 0.0% | -81.5% | 0.0% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| Design Therapeutics Inc (DSGN) | $670.46M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $445.38M | N/A | 5.0x | 0.0% | -7.4% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Neurogene, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Regenxbio Inc (RGNX) | REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable... | RGNX competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| PepGen Ltd (PEPG) | PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious... | PEPG competitors |
| Opus Genetics, Inc. (IRD) | Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. | IRD competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| Geron Corporation (GERN) | Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic... | GERN competitors |
| Ginkgo Bioworks Holdings (DNA) | Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms... | DNA competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health... | KYTX competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
| Design Therapeutics Inc (DSGN) | Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. | DSGN competitors |
Frequently Asked Questions About NGNE
Who are Neurogene's main competitors?
The companies most similar to Neurogene include Regenxbio (RGNX), Gyre Therapeutics (GYRE), PepGen (PEPG), Opus Genetics (IRD) and Tevogen Bio Holdings (TVGN), listed from the closest match.
Who is Neurogene's biggest competitor?
Nuvectis Pharma (NVCT) is the largest of the similar companies at $696.03M; Regenxbio (RGNX) is the closest match by business profile, size, sector and industry.
How does NGNE stock compare with its competitors?
NGNE's net margin is 0.0% against a peer median of 0.0%.
Which of Neurogene's competitors pays a higher dividend?
Neurogene pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Neurogene bigger than its competitors?
No. Neurogene is 6th by market cap among the 13 companies on this page; the largest is Nuvectis Pharma (NVCT) at $696.03M.
NGNE pages: Overview, Earnings, Forecast, Financials, Competitors